Browsing Tag
Viatris
15 posts
Viatris and the presbyopia drug race: What ASCRS 2026 data means for the MR-141 FDA decision in October
Viatris presents full VEGA-3 Phase 3 data for MR-141 presbyopia drop at ASCRS 2026. FDA PDUFA date is October 17, 2026. Market context, competitive landscape, and investor outlook.
ASCRS 2026 in Washington DC: What ophthalmologists need to know
ASCRS 2026 annual meeting runs April 10-13 in Washington DC. Full guide to the programme, key speakers, technology announcements, SightLine, and CME for anterior segment surgeons.
Biocon goes all-in on biosimilars with $5.5bn Biocon Biologics merger and Viatris exit
Biocon to merge Biocon Biologics in $5.5B deal with full ownership via share swap and cash. Find out what it means for investors and global biosimilar strategy.
Phase 2 trial of Nasus Pharma’s NS002 needle-free epinephrine starts with initial dosing milestone
Find out how Nasus Pharma is advancing NS002, its needle-free intranasal epinephrine candidate, into Phase 2 trials and what it means for emergency allergy care.
Safecor Health to acquire UDL from Viatris to expand pharmaceutical unit-dose solutions
Safecor Health, a leader in pharmaceutical unit-dose repackaging and supply chain solutions, has announced its acquisition of the…
Sandoz and Biocon Biologics sign distribution deal for key immunology drug
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd and a prominent player in the global biosimilars market,…
Biocon Biologics wraps up integration of Viatris’ biosimilars business in Europe
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful completion of the integration of…
Viatris Inc. announces divestitures in key business sectors: Comprehensive breakdown
Viatris Inc. (NASDAQ: VTRS), a frontrunner in global healthcare, has unveiled a series of divestitures in its business…
Biocon Biologics wraps up integration of former Viatris biosimilars business
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful integration of the acquired biosimilars…
Biocon Biologics debuts biosimilar HULIO in US market
In a significant development for healthcare accessibility, Biocon Biologics Ltd (BBL), a subsidiary of Biocon, announced the availability…